IMPORTANCE: To make good decisions about prostate-specific antigen (PSA) screening, men must consider how they value the different potential outcomes. OBJECTIVE: To determine the effects of different methods of helping men consider such values. DESIGN AND SETTING: Randomized trial from October 12 to 27, 2011, in the general community. PARTICIPANTS: A total of 911 men aged 50 to 70 years from the United States and Australia who had average risk. Participants were drawn from online panels from a survey research firm in each country and were randomized by the survey firm to 1 of 3 values clarification methods: a balance sheet (n = 302), a rating and ranking task (n = 307), or a discrete choice experiment (n = 302). INTERVENTION: Participants underwent a values clarification task and then chose the most important attribute. MAIN OUTCOME MEASURES: The main outcome was the difference among groups in the most important attribute. Secondary outcomes were differences in unlabeled test preference and intent to undergo screening with PSA. RESULTS:The mean age was 59.8 years; most participants were white and more than one-third had graduated from college. More than 40% reported a PSA test within 12 months. The participants who received the rating and ranking task were more likely to report reducing the chance of death from prostate cancer as being most important (54.4%) compared with those who received the balance sheet (35.1%) or the discrete choice experiment (32.5%) (P < .001). Those receiving the balance sheet were more likely (43.7%) to prefer the unlabeled PSA-like option (as opposed to the "no screening"-like option) compared with those who received rating and ranking (34.2%) or the discrete choice experiment (20.2%). However, the proportion who intended to undergo PSA testing was high and did not differ between groups (balance sheet, 77.1%; rating and ranking, 76.8%; and discrete choice experiment, 73.5%; P = .73). CONCLUSIONS AND RELEVANCE: Different values clarification methods produce different patterns of attribute importance and different preferences for screening when presented with an unlabeled choice. Further studies with more distal outcome measures are needed to determine the best method of values clarification, if any, for decisions such as whether to undergo screening with PSA.
RCT Entities:
IMPORTANCE: To make good decisions about prostate-specific antigen (PSA) screening, men must consider how they value the different potential outcomes. OBJECTIVE: To determine the effects of different methods of helping men consider such values. DESIGN AND SETTING: Randomized trial from October 12 to 27, 2011, in the general community. PARTICIPANTS: A total of 911 men aged 50 to 70 years from the United States and Australia who had average risk. Participants were drawn from online panels from a survey research firm in each country and were randomized by the survey firm to 1 of 3 values clarification methods: a balance sheet (n = 302), a rating and ranking task (n = 307), or a discrete choice experiment (n = 302). INTERVENTION: Participants underwent a values clarification task and then chose the most important attribute. MAIN OUTCOME MEASURES: The main outcome was the difference among groups in the most important attribute. Secondary outcomes were differences in unlabeled test preference and intent to undergo screening with PSA. RESULTS: The mean age was 59.8 years; most participants were white and more than one-third had graduated from college. More than 40% reported a PSA test within 12 months. The participants who received the rating and ranking task were more likely to report reducing the chance of death from prostate cancer as being most important (54.4%) compared with those who received the balance sheet (35.1%) or the discrete choice experiment (32.5%) (P < .001). Those receiving the balance sheet were more likely (43.7%) to prefer the unlabeled PSA-like option (as opposed to the "no screening"-like option) compared with those who received rating and ranking (34.2%) or the discrete choice experiment (20.2%). However, the proportion who intended to undergo PSA testing was high and did not differ between groups (balance sheet, 77.1%; rating and ranking, 76.8%; and discrete choice experiment, 73.5%; P = .73). CONCLUSIONS AND RELEVANCE: Different values clarification methods produce different patterns of attribute importance and different preferences for screening when presented with an unlabeled choice. Further studies with more distal outcome measures are needed to determine the best method of values clarification, if any, for decisions such as whether to undergo screening with PSA.
Authors: Deborah Marshall; John F P Bridges; Brett Hauber; Ruthanne Cameron; Lauren Donnalley; Ken Fyie; F Reed Johnson Journal: Patient Date: 2010-12-01 Impact factor: 3.883
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245
Authors: Dawn Stacey; Carol L Bennett; Michael J Barry; Nananda F Col; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; France Légaré; Richard Thomson Journal: Cochrane Database Syst Rev Date: 2011-10-05
Authors: Esther W de Bekker-Grob; Lieke Hol; Bas Donkers; Leonie van Dam; J Dik F Habbema; Monique E van Leerdam; Ernst J Kuipers; Marie-Louise Essink-Bot; Ewout W Steyerberg Journal: Value Health Date: 2009-11-12 Impact factor: 5.725
Authors: Glyn Elwyn; Annette M O'Connor; Carol Bennett; Robert G Newcombe; Mary Politi; Marie-Anne Durand; Elizabeth Drake; Natalie Joseph-Williams; Sara Khangura; Anton Saarimaki; Stephanie Sivell; Mareike Stiel; Steven J Bernstein; Nananda Col; Angela Coulter; Karen Eden; Martin Härter; Margaret Holmes Rovner; Nora Moumjid; Dawn Stacey; Richard Thomson; Tim Whelan; Trudy van der Weijden; Adrian Edwards Journal: PLoS One Date: 2009-03-04 Impact factor: 3.240
Authors: Alison Brenner; Kirsten Howard; Carmen Lewis; Stacey Sheridan; Trisha Crutchfield; Sarah Hawley; Dan Reuland; Christine Kistler; Michael Pignone Journal: J Gen Intern Med Date: 2013-11-23 Impact factor: 5.128
Authors: Clara Nan-Hi Lee; Allison M Deal; Ruth Huh; Peter Anthony Ubel; Yuen-Jong Liu; Lillian Blizard; Caprice Hunt; Michael Patrick Pignone Journal: JAMA Surg Date: 2017-08-01 Impact factor: 14.766